Top

Published in:

Open Access 01-12-2014 | Oral presentation

Reimbursement of orphan drugs: the Pompe and Fabry case in the Netherlands

Author: Rinke van den Brink

Published in: Orphanet Journal of Rare Diseases | Special Issue 1/2014

Excerpt

By the end of June 2012 NOS News got hold of a concept advice to the Minister of Health. It proposed to stop the reimbursement of the orphan drugs Myozyme against Pompe’s disease and Fabryzyme and Replagal against Fabry’s disease. All three enzyme-therapies are very expensive. The treatment for Pompe-patients costs roughly between € 400.000 and € 700.000 a year, for Fabry-patients about € 220.000 a year. The main argument for stopping the compensation was the cost-ineffectiveness of the enzyme-therapy. In other words: too much money for too little result. …

Title: Reimbursement of orphan drugs: the Pompe and Fabry case in the Netherlands
Author: Rinke van den Brink
Publication date: 01-12-2014
Publisher: BioMed Central
Published in: Orphanet Journal of Rare Diseases / Issue Special Issue 1/2014
Electronic ISSN: 1750-1172
DOI: https://doi.org/10.1186/1750-1172-9-S1-O17

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Reimbursement of orphan drugs: the Pompe and Fabry case in the Netherlands

Excerpt

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Special Issue 1/2014

Towards a European platform for Rare Diseases Registries

Perspective having a Centre of Expertise that covers more than one rare disease

Characterization and classification of Rare Disease Registries by using exploratory data analyses

Preserving the owner’s autonomy in networks of patient registries and biobanks

Use of animal models for exome prioritization of rare disease genes

FindZebra - the search engine for difficult medical cases